Magnetic resonance imaging-transrectal ultrasound cognitive fusion targeted biopsy on the diagnosis of prostate cancer: a research of 614 cases in single center.
10.7507/1001-5515.201911076
- Author:
Derun LI
1
,
2
,
3
;
Yi LIU
1
,
2
,
3
;
Zhihua LI
1
,
2
,
3
;
Shuqing LI
1
,
2
,
3
;
Gangzhi SHAN
1
,
2
,
3
;
Lin YAO
1
,
2
,
3
Author Information
1. Department of Urology, Peking University First Hospital, Beijing 100034, P.R.China
2. Institute of Urology, Peking University, Beijing 100034, P.R.China
3. National Urological Cancer Center, Beijing 100034, P.R.China.
- Publication Type:Journal Article
- Keywords:
cognitive fusion targeted biopsy;
targeted biopsy;
transrectal prostate biopsy
- MeSH:
Biopsy;
methods;
Humans;
Image-Guided Biopsy;
Magnetic Resonance Imaging, Interventional;
Male;
Prospective Studies;
Prostatic Neoplasms;
diagnostic imaging;
Ultrasonography, Interventional
- From:
Journal of Biomedical Engineering
2020;37(2):225-229
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to compare the prostate cancer detection rate between magnetic resonance imaging (MRI)-transrectal ultrasound (TRUS) cognitive fusion targeted biopsy and systematic biopsy. A total of 614 patients who underwent transrectal prostate biopsy during 2016-2018 with multiparametric magnetic resonance imaging (mpMRI) were included. All patients with a PI-RADS V2 score ≥ 3 accepted both targeted biopsy and systematic biopsy, and those with a PI-RADS V2 score ≤ 2 only accepted systematic biopsy. Overall prostate cancer detection rate between the two biopsies was compared. MRI-TRUS cognitive fusion targeted biopsy identified 342 cases (75.7%) of prostate cancer while systematic biopsy identified 358 cases (79.2%). There was no significant difference in the detection rate between the two groups ( = 1.621, = 0.203). Targeted biopsy had significant fewer biopsy cores compared with systematic biopsy, reducing (9.3 ± 0.11) cores ( < 0.001) in average. Targeted biopsy had about 10.8% ( < 0.001) more tumor tissues in positive cores compared with systematic biopsy. The results show that both MRI-TRUS cognitive fusion targeted biopsy and systematic biopsy have good detection rate on prostate cancer. Cognitive targeted biopsy may reduce biopsy cores and provide more tumor tissues in positive cores.
